Cited 3 times in
Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2023-08-09T02:48:20Z | - |
dc.date.available | 2023-08-09T02:48:20Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195854 | - |
dc.description.abstract | It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA. Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes. The median progression free survival(PFS) was 9.2 months (range 7.7 - 10.7 months) vs 28.9 months (range 22.6 - 35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group. Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Da Jung Kim | - |
dc.contributor.googleauthor | Ho Sup Lee | - |
dc.contributor.googleauthor | Joon-Ho Moon | - |
dc.contributor.googleauthor | Sang Kyun Sohn | - |
dc.contributor.googleauthor | Hyeoung Joon Kim | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Deog-Yeon Jo | - |
dc.contributor.googleauthor | Hawk Kim | - |
dc.contributor.googleauthor | Hyewon Lee | - |
dc.contributor.googleauthor | Soo-Mee Bang | - |
dc.contributor.googleauthor | Won Sik Lee | - |
dc.contributor.googleauthor | Yong Park | - |
dc.contributor.googleauthor | Mark Hong Lee | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Sung Hwa Bae | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Korean Society of Hematology AML/MDS Working Party | - |
dc.identifier.doi | 10.18632/oncotarget.18258 | - |
dc.contributor.localId | A03729 | - |
dc.contributor.localId | A01512 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 29108320 | - |
dc.subject.keyword | azacitidine | - |
dc.subject.keyword | decitabine | - |
dc.subject.keyword | discontinuation | - |
dc.subject.keyword | myelodysplastic syndrome | - |
dc.subject.keyword | survival | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | 정준원 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 45 | - |
dc.citation.startPage | 79414 | - |
dc.citation.endPage | 79424 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, Vol.8(45) : 79414-79424, 2017-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.